Immuneering Corporation (IMRX) Financial Statements (2025 and earlier)

Company Profile

Business Address 245 MAIN STREET, SECOND FLOOR
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments85,666105,525149,199
Cash and cash equivalents59,40672,63774,888
Short-term investments26,26032,88874,311
Receivables  12246
Other undisclosed current assets3,4183,2102,889
Total current assets:89,084108,747152,334
Noncurrent Assets
Operating lease, right-of-use asset3,9964,4085,324
Property, plant and equipment1,4011,370807
Long-term investments and receivables   997
Long-term investments   997
Intangible assets, net (including goodwill)7,0707,0997,141
Goodwill6,6906,6906,702
Intangible assets, net (excluding goodwill)380409439
Other noncurrent assets1,034744102
Total noncurrent assets:13,50113,62014,371
TOTAL ASSETS:102,585122,367166,705
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,2867,6565,360
Accounts payable2,1123,1551,394
Accrued liabilities5,1744,5013,965
Other liabilities26020 
Other undisclosed current liabilities300379274
Total current liabilities:7,8468,0545,634
Noncurrent Liabilities
Long-term debt and lease obligation:   5,091
Liabilities, other than long-term debt4,1634,463 
Operating lease, liability4,1634,4635,091
Other undisclosed noncurrent liabilities   (5,091)
Total noncurrent liabilities:4,1634,4635,091
Total liabilities:12,00812,51710,725
Equity
Equity, attributable to parent, including:90,576109,850155,980
Additional paid in capital253,806219,641215,276
Accumulated other comprehensive income (loss)(1)(30)(49)
Accumulated deficit(163,259)(109,787)(59,273)
Other undisclosed equity, attributable to parent292626
Total equity:90,576109,850155,980
TOTAL LIABILITIES AND EQUITY:102,585122,367166,705

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Revenues1483172,080
Sublease income148  
Cost of revenue  (158)(1,153)
Gross profit:148159927
Operating expenses(58,413)(51,904)(34,813)
Other undisclosed operating loss(148)  
Operating loss:(58,413)(51,745)(33,886)
Nonoperating income4,9411,23143
Investment income, nonoperating3,6071,014170
Other nonoperating income (expense)1,334217(127)
Loss from continuing operations before income taxes:(53,472)(50,514)(33,843)
Income tax benefit   307
Loss from continuing operations:(53,472)(50,514)(33,536)
Loss before gain (loss) on sale of properties:(33,536)
Net loss available to common stockholders, diluted:(53,472)(50,514)(33,536)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net loss:(53,472)(50,514)(33,536)
Other comprehensive income (loss)  19(49)
Comprehensive loss:(53,472)(50,495)(33,585)
Other undisclosed comprehensive income, net of tax, attributable to parent29  
Comprehensive loss, net of tax, attributable to parent:(53,442)(50,495)(33,585)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: